Discovery of 6-N,N-Bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a Novel Selective Androgen Receptor Modulator
- 22 September 2006
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (21) , 6143-6146
- https://doi.org/10.1021/jm060792t
Abstract
The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.Keywords
This publication has 17 references indexed in Scilit:
- Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and EndometriosisEndocrine Reviews, 2005
- Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolismThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Recognition and Accommodation at the Androgen Receptor Coactivator Binding InterfacePLoS Biology, 2004
- Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor ModulatorsJournal of Medicinal Chemistry, 2004
- Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadismClinical Endocrinology, 2003
- Evidence for Tissue Selectivity of the Synthetic Androgen 7α-Methyl-19-Nortestosterone in Hypogonadal MenJournal of Clinical Endocrinology & Metabolism, 2003
- A Nonsteroidal Glucocorticoid Receptor AntagonistMolecular Endocrinology, 2003
- Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New MillenniumJournal of Clinical Endocrinology & Metabolism, 1999
- Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)Journal of Medicinal Chemistry, 1999
- Transdermal Delivery of Testosterone*Journal of Clinical Endocrinology & Metabolism, 1987